Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia

Most patients with acute myelogenous leukemia (AML) relapse and die of their disease. Increasing evidence indicates that AML relapse is driven by the inability to eradicate leukemia stem cells (LSC). Thus, it is imperative to identify novel therapies that can ablate LSCs. Using an in silico gene exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzman, Monica L., Yang, Neng, Sharma, Krishan K., Balys, Marlene, Corbett, Cheryl A., Jordan, Craig T., Becker, Michael W., Steidl, Ulrich, Abdel-Wahab, Omar, Levine, Ross L., Marcucci, Guido, Roboz, Gail J., Hassane, Duane C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383047/
https://www.ncbi.nlm.nih.gov/pubmed/24934933
http://dx.doi.org/10.1158/1535-7163.MCT-13-0963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383047/
https://www.ncbi.nlm.nih.gov/pubmed/24934933
http://dx.doi.org/10.1158/1535-7163.MCT-13-0963

Ejemplares similares